The dual PPARα/γ agonist tesaglitazar blocks progression of pre‐existing atherosclerosis in APOE*3Leiden.CETP transgenic mice
Open Access
- 31 March 2009
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 156 (7) , 1067-1075
Abstract
Background and purpose: We have evaluated the effects of a peroxisome proliferator‐activated receptor (PPAR)α/γ agonist on the progression of pre‐existing atherosclerotic lesions in APOE*3Leiden.cholesteryl ester transfer protein (E3L.CETP) transgenic mice.Experimental approach: E3L.CETP mice were fed a high‐cholesterol diet for 11 weeks to induce atherosclerosis, followed by a low‐cholesterol diet for 4 weeks to obtain a lower plasma total cholesterol level of ∼10 mmol·L−1. Mice were divided into three groups, which were either killed before (baseline) or after an 8 week treatment period with low‐cholesterol diet without (control) or with the PPARα/γ agonist tesaglitazar (10 µg·kg−1·day−1). Atherosclerosis was assessed in the aortic root.Key results: Treatment with tesaglitazar significantly reduced plasma triglycerides, total cholesterol, CETP mass and CETP activity, and increased high‐density lipoprotein‐cholesterol. At baseline, substantial atherosclerosis had developed. During the 8 week low‐cholesterol diet, atherosclerosis progressed in the control group with respect to lesion area and severity, whereas tesaglitazar inhibited lesion progression during this period. Tesaglitazar reduced vessel wall inflammation, as reflected by decreased monocyte adhesion and macrophage area, and modified lesions to a more stabilized phenotype, with increased smooth muscle cell content in the cap and collagen content.Conclusions and implications: Dual PPARα/γ agonism with tesaglitazar markedly improved the atherogenic triad by reducing triglycerides and very low‐density lipoprotein‐cholesterol and increasing high‐density lipoprotein‐cholesterol and additionally reduced cholesterol‐induced vessel wall activation. These actions resulted in complete inhibition of progression and stabilization of pre‐existing atherosclerotic lesions in E3L.CETP mice.Keywords
This publication has 49 references indexed in Scilit:
- Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic miceJournal Of Hypertension, 2007
- Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient miceAtherosclerosis, 2007
- Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ AgonistsThe American Journal of Cardiology, 2007
- FenofibrateDrugs, 2007
- Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12‐week dose-ranging trialCurrent Medical Research and Opinion, 2006
- Fenofibrate Reduces Atherogenesis in ApoE*3Leiden MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.Journal of Clinical Investigation, 1994
- High-Density Lipoprotein — The Clinical Implications of Recent StudiesNew England Journal of Medicine, 1989
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987